245 related articles for article (PubMed ID: 35454875)
1. Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions.
Żak K; Zaremba B; Rajtak A; Kotarski J; Amant F; Bobiński M
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454875
[TBL] [Abstract][Full Text] [Related]
2. DNA fragmentation factors 40 and 45 (DFF40/DFF45) and B-cell lymphoma 2 (Bcl-2) protein are underexpressed in uterine leiomyosarcomas and may predict survival.
Banas T; Pitynski K; Okon K; Czerw A
Onco Targets Ther; 2017; 10():4579-4589. PubMed ID: 29075126
[TBL] [Abstract][Full Text] [Related]
3. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Sahly NN; Banaganapalli B; Sahly AN; Aligiraigri AH; Nasser KK; Shinawi T; Mohammed A; Alamri AS; Bondagji N; Elango R; Shaik NA
Syst Biol Reprod Med; 2021 Jun; 67(3):209-220. PubMed ID: 33685300
[TBL] [Abstract][Full Text] [Related]
4. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
5. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
[TBL] [Abstract][Full Text] [Related]
6. Serum microRNA profile enables preoperative diagnosis of uterine leiomyosarcoma.
Yokoi A; Matsuzaki J; Yamamoto Y; Tate K; Yoneoka Y; Shimizu H; Uehara T; Ishikawa M; Takizawa S; Aoki Y; Kato K; Kato T; Ochiya T
Cancer Sci; 2019 Dec; 110(12):3718-3726. PubMed ID: 31599471
[TBL] [Abstract][Full Text] [Related]
7. Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center.
Peters A; Sadecky AM; Winger DG; Guido RS; Lee TTM; Mansuria SM; Donnellan NM
Int J Gynecol Cancer; 2017 Jul; 27(6):1183-1190. PubMed ID: 28463949
[TBL] [Abstract][Full Text] [Related]
8. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization.
Levy B; Mukherjee T; Hirschhorn K
Cancer Genet Cytogenet; 2000 Aug; 121(1):1-8. PubMed ID: 10958933
[TBL] [Abstract][Full Text] [Related]
9. Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.
Tantari M; Barra F; Di Domenico S; Ferraioli D; Vellone VG; De Cian F; Ferrero S
Expert Opin Pharmacother; 2019 Apr; 20(6):713-723. PubMed ID: 30724615
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
11. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy.
Danielson LS; Menendez S; Attolini CS; Guijarro MV; Bisogna M; Wei J; Socci ND; Levine DA; Michor F; Hernando E
Am J Pathol; 2010 Aug; 177(2):908-17. PubMed ID: 20558575
[TBL] [Abstract][Full Text] [Related]
12. Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma.
Abedin Y; Gabrilovich S; Alpert E; Rego E; Begum S; Zhao Q; Heller D; Einstein MH; Douglas NC
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682660
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma.
Deng Y; Han Q; Mei S; Li H; Yang F; Wang J; Ge S; Jing X; Xu H; Zhang T
Oncol Lett; 2019 Sep; 18(3):2845-2852. PubMed ID: 31452763
[TBL] [Abstract][Full Text] [Related]
14. Let-7 repression leads to HMGA2 overexpression in uterine leiomyosarcoma.
Shi G; Perle MA; Mittal K; Chen H; Zou X; Narita M; Hernando E; Lee P; Wei JJ
J Cell Mol Med; 2009 Sep; 13(9B):3898-905. PubMed ID: 19602040
[TBL] [Abstract][Full Text] [Related]
15. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new.
Hwang H; Matsuo K; Duncan K; Pakzamir E; Pham HQ; Correa A; Fedenko A; Mhawech-Fauceglia P
J Clin Pathol; 2015 Sep; 68(9):710-7. PubMed ID: 25991737
[TBL] [Abstract][Full Text] [Related]
17. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
18. Serum YKL-40 Level Positively Correlates With Uterine Leiomyomas.
Guo W; Wang J; Wei H
Reprod Sci; 2016 Nov; 23(11):1559-1564. PubMed ID: 27170664
[TBL] [Abstract][Full Text] [Related]
19. The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma.
Hinchcliff EM; Esselen KM; Watkins JC; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Quade BJ; Muto MG
J Minim Invasive Gynecol; 2016; 23(4):567-72. PubMed ID: 26851414
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
